Vericel (VCEL) Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase 2024 summary

Key product and market insights

• Portfolio includes advanced autologous cell therapies and specialty biologics for sports medicine and severe burn care.

• MACI is the only FDA-approved cartilage repair product, addressing a $3B+ knee market and expanding into ankle indications.

• NexoBrid and Epicel serve severe burn care, with NexoBrid offering a less traumatic eschar removal and Epicel as the only FDA-approved permanent skin replacement for large burns.

• Combined burn care market opportunity exceeds $500M, with NexoBrid and Epicel each representing ~$300M annually.

• Significant competitive barriers exist due to regulatory exclusivity and lack of generic pathways.

Financial performance and growth

• Achieved record Q2 revenue of $53M, with 20% company-wide growth in the first half of the year.

• Gross margins reached 70% in Q2, up 400 basis points year-over-year, and adjusted earnings grew 42%.

• Four consecutive years of positive adjusted earnings and operating cash flow; ended Q2 with $154M in cash and no debt.

• Guidance for 2023 is $238M–$242M in revenue, 71% gross margins, and 21% adjusted EBITDA margin.

• Burn care franchise expected to grow 30% this year, with durable 20%+ growth projected for the overall business.

Pipeline and strategic initiatives

• MACI Arthro, an arthroscopic delivery, is expected to launch soon, targeting the largest segment of the knee cartilage market.

• Study for MACI in ankle cartilage defects to begin next year, addressing a $1B opportunity.

• NexoBrid pediatric indication expected this quarter, expanding reach to 20 additional pediatric burn centers.

• Commercial strategy includes expanding the surgeon base and adding a dozen sales and arthroscopic specialists.

• Minimal commercial investment anticipated for new launches, leveraging existing infrastructure.